|
|
29 Emmons Drive Suite C-10
Princeton, NJ 08540 USA
phone:(609)-538-8200
fax:
|
|
| Symbol |
SNGX.OB |
| Exchange |
OTC-BB |
| Founded |
1987 |
| Employees |
12 |
|
|
| www.soligenix.com
|
|
|
|
 |
| Summary Description |
| Developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents |
|
| Management |
| Evan Myrianthopoulos, Senior Vice-President and CFO;
Christopher J Schaber, PhD, President and CEO |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| Bioterrorism, Oncology, |
|
|
|
|
|
|
| Description |
|
Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec TM (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation. |
|
| Products / Services |
Soligenix, Inc. (Soligenix) (OTCBB: SNGX) is a latestage biopharmaceutical company developing products
to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases,
and vaccines for selected bioterrorism agents. Soligenixâ??s lead product, orBec® (oral beclamethasone
diproprionate or BDP), is a potent, locally acting corticosteroid being developed for treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening
complication of hematopoietic cell transplantation (HCT).
www.soligenix.com
|
|
| Technology / Differentiation |
Soligenix is developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Soligenix's lead product, orBec TM (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation (HCT).
orBec� represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of GVHD by reducing the need for systemic immunosuppressive drugs. BDP is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. orBec� is uniquely formulated for oral administration as a single product consisting of two tablets: one intended to release BDP in the upper portions of the GI tract, and the other in the distal portions.
Soligenix has reached agreement with the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) on the design of a confirmatory, Phase 3, double-blind, randomized, placebo-controlled clinical study evaluating the safety and efficacy of orBec® for the treatment of acute GI GVHD. The agreed clinical trial design is the subject of a Special Protocol Assessment (SPA) agreement with the FDA. This study is currently enrolling patients and is targeted to complete in the first half of 2011. orBec® is also currently the subject of an NIH-supported Phase 2, randomized, double-blind, placebo-controlled clinical study for the prevention of acute GVHD. This study has completed enrollment and results are expected in the second half of 2010.
Soligenix is also developing oral BDP for the prevention/treatment of other gastrointestinal disorders characterized by severe inflammation, including acute radiation enteritis (SGX201), radiation injury (SGX202) and Crohn's disease (SGX203). A Phase 1/2 study of SGX201 in radiation enteritis has been initiated and is targeted to complete in the first half of 2011.
In addition, Soligenix is developing its proprietary Lipid Polymer Micelle (LPM) drug delivery technology to enhance the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis. |
|
| Market / Customers |
Publicly traded company
|
|
| Strategy |
Stock Snapshot
OTC BB: SNGX
Recent Stock Price: $0.27
Market Cap: $50 million as of May 31, 2010
Soligenix, Inc. is a late-stage biopharmaceutical company committed to the development of life-saving therapeutics and vaccines. Soligenix has two areas of focus: 1) a therapeutics platform dedicated to the development of products for life-threatening conditions such as gastrointestinal Graft-versus-Host disease and cancer, and 2) a biodefense platform to develop vaccines for military and civilian applications.
|
|
| Status |
| Recent Stock Price: $0.27
Market Cap: $50 million as of
May 31, 2010
Soligenix, Inc. is a late-stage biopharmaceutical company committed to the development of life-saving therapeutics and vaccines. Soligenix has two areas of focus: 1) a therapeutics platform dedicated to the development of products for life-threatening conditions such as gastrointestinal Graft-versus-Host disease and cancer, and 2) a biodefense platform to develop vaccines for military and civilian applications. |
|
| Analyst Coverage |
| 2 analysts. National and Griffen. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members